HK1129277A1 - Tannate salt of rasagiline - Google Patents

Tannate salt of rasagiline

Info

Publication number
HK1129277A1
HK1129277A1 HK09109429.3A HK09109429A HK1129277A1 HK 1129277 A1 HK1129277 A1 HK 1129277A1 HK 09109429 A HK09109429 A HK 09109429A HK 1129277 A1 HK1129277 A1 HK 1129277A1
Authority
HK
Hong Kong
Prior art keywords
rasagiline
tannate salt
tannate
salt
compositions
Prior art date
Application number
HK09109429.3A
Other languages
English (en)
Inventor
Anton Frenkel
Tamas Koltai
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HK1129277A1 publication Critical patent/HK1129277A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HK09109429.3A 2006-12-14 2009-10-13 Tannate salt of rasagiline HK1129277A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87503806P 2006-12-14 2006-12-14
PCT/US2007/025516 WO2008076315A1 (en) 2006-12-14 2007-12-13 Tannate salt of rasagiline

Publications (1)

Publication Number Publication Date
HK1129277A1 true HK1129277A1 (en) 2009-11-27

Family

ID=39536617

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09109429.3A HK1129277A1 (en) 2006-12-14 2009-10-13 Tannate salt of rasagiline

Country Status (24)

Country Link
US (1) US7547806B2 (ja)
EP (1) EP2101570B1 (ja)
JP (1) JP5356248B2 (ja)
KR (1) KR101077835B1 (ja)
CN (1) CN101600346B (ja)
AU (1) AU2007334493B2 (ja)
BR (1) BRPI0718339A2 (ja)
CA (1) CA2672452C (ja)
DK (1) DK2101570T3 (ja)
EA (1) EA016843B1 (ja)
ES (1) ES2420124T3 (ja)
HK (1) HK1129277A1 (ja)
HR (1) HRP20130396T1 (ja)
IL (1) IL198984A (ja)
MX (1) MX2009006252A (ja)
NO (1) NO20092609L (ja)
NZ (1) NZ577623A (ja)
PL (1) PL2101570T3 (ja)
PT (1) PT2101570E (ja)
RS (1) RS52784B (ja)
SI (1) SI2101570T1 (ja)
UA (1) UA97382C2 (ja)
WO (1) WO2008076315A1 (ja)
ZA (1) ZA200903904B (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
JP5738509B2 (ja) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
US7491847B2 (en) * 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101442997B (zh) * 2006-04-03 2012-11-14 泰华制药工业有限公司 雷沙吉兰用于治疗多动腿综合征
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
AU2007334428B2 (en) 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
NZ577623A (en) 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2285214B1 (en) * 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
WO2009154782A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
AU2009260728B2 (en) 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
EP2451771B1 (en) 2009-07-09 2014-06-18 Ratiopharm GmbH Salts of rasagiline and pharmaceutical preparations thereof
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
US20110152381A1 (en) * 2009-12-22 2011-06-23 Anton Frenkel 3-keto-n-propargyl-1-aminoindan
US20120269871A1 (en) 2009-12-30 2012-10-25 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
WO2011095985A2 (en) * 2010-02-02 2011-08-11 Glenmark Generics Limited Rasagiline salts and processes for the preparation thereof
JP2013533287A (ja) 2010-07-27 2013-08-22 テバ ファーマシューティカル インダストリーズ リミティド 嗅覚機能不全の処置のためのラサギリンの使用
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
MX343986B (es) 2012-03-21 2016-12-01 Synthon Bv Composiciones farmaceuticas estabilizadas que comprenden sales de rasagilina.
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
CA2945681A1 (en) * 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Sitagliptin tannate complex
CN107125438A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂鞣酸生物碱及其制备方法以及一种复合添加剂和一种饲料
TW201818969A (zh) * 2016-10-19 2018-06-01 日商帝化製藥股份有限公司 在生體內之藥物溶出控制用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) * 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL130528A (en) 1996-12-18 2004-12-15 Teva Pharma Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
WO2002005745A2 (en) * 2000-07-14 2002-01-24 Cadila Pharmaceuticals Limited The process of manufacturing pharmaceutical grade tannates
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US6869618B2 (en) 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
EP2526944B1 (en) * 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
DE602004017166D1 (de) * 2003-03-25 2008-11-27 Kiel Lab Inc Gabapentintannat in flüssigen und/oder halbfesten dosierformen
US7875630B2 (en) * 2003-09-03 2011-01-25 Glaxo Group Limited Process salts compositions and use
WO2005025573A1 (en) * 2003-09-05 2005-03-24 P3 Laboratories, Inc. Compositions and methods for treating pain
US20050202050A1 (en) * 2004-03-12 2005-09-15 Kiel Jeffrey S. Single tank process for preparing tannate liquid and semi-solid dosage forms
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
AU2005309817B2 (en) 2004-11-24 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
JP5738509B2 (ja) * 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
US7491847B2 (en) * 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
EP1991214B1 (en) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101442997B (zh) * 2006-04-03 2012-11-14 泰华制药工业有限公司 雷沙吉兰用于治疗多动腿综合征
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
NZ577623A (en) 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff

Also Published As

Publication number Publication date
AU2007334493B2 (en) 2010-12-02
BRPI0718339A2 (pt) 2014-02-18
EA016843B1 (ru) 2012-07-30
KR20090088433A (ko) 2009-08-19
US7547806B2 (en) 2009-06-16
UA97382C2 (ru) 2012-02-10
JP2010513280A (ja) 2010-04-30
NZ577623A (en) 2011-05-27
ES2420124T3 (es) 2013-08-22
RS52784B (en) 2013-10-31
EA200970580A1 (ru) 2009-12-30
CN101600346A (zh) 2009-12-09
CA2672452A1 (en) 2008-06-26
CN101600346B (zh) 2013-08-21
HRP20130396T1 (en) 2013-06-30
EP2101570B1 (en) 2013-02-13
PT2101570E (pt) 2013-05-17
CA2672452C (en) 2012-07-03
ZA200903904B (en) 2010-08-25
EP2101570A1 (en) 2009-09-23
US20080146676A1 (en) 2008-06-19
EP2101570A4 (en) 2011-04-06
KR101077835B1 (ko) 2011-10-28
MX2009006252A (es) 2009-10-13
WO2008076315A1 (en) 2008-06-26
SI2101570T1 (sl) 2013-06-28
DK2101570T3 (da) 2013-05-27
PL2101570T3 (pl) 2013-07-31
IL198984A (en) 2013-03-24
IL198984A0 (en) 2010-02-17
AU2007334493A1 (en) 2008-06-26
NO20092609L (no) 2009-09-04
JP5356248B2 (ja) 2013-12-04

Similar Documents

Publication Publication Date Title
HK1129277A1 (en) Tannate salt of rasagiline
EG25147A (en) Process for the manufacture of 1,2-dichloroethane.
UA97502C2 (ru) Кристаллическая твердая основа разагилина
DK3872059T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
WO2007093627A3 (de) Biozide zusammensetzung
EG25812A (en) Process for the manufacture of 1,2-dichloroethane
MX284139B (es) Produccion de isoprenoides.
TW200745261A (en) Aqueous dispersions based on nitrocellulose-polyurethane particles
ZA200904333B (en) Process for the preparation of 6,6-Dimethyl-3-azabicyclo-[3.1.0]-hexane compounds utilizing bisulfite intermediate
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
TW200833649A (en) Method for the preparation of hydroxyadamantanamine
MX2009009490A (es) Profarmacos novedosos.
TW200734339A (en) Forms of dolasetron mesylate and processes for their preparation
TW200637832A (en) Process for preparing amorphous valsartan
WO2008015584A3 (en) Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof
EG25292A (en) Process for the production of anilines.
EP1996192A4 (en) PROCESS FOR PREPARING 3,4-SUBSTITUTED THIAZOLIDIN-2-ONES IN 3,4
IL192153A0 (en) Process for manufacturing entacapone
WO2008090465A3 (en) Process for synthesizing desvenlafaxine free base and salts or salvates thereof
WO2008029267A3 (de) Hydrochloride von 3-amino-2-hydroxycarbonsäureamiden
MX2009003196A (es) Proceso para la preparacion de y-butirolactonas.
EP1915380A4 (en) PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES
WO2008038146A3 (en) Improved processes for preparing vanlafaxine base and salts thereof
PL382315A1 (pl) Sposób wytwarzania S-(-)-6-metoksy-1, 2, 3, 4-tetrahydro-2-naftolu

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161213